SCHEDULE 1.6

                         CAT BACKGROUND PATENT RIGHTS

1    "Single Domain Ligands, Receptors Comprising said Ligands, Methods for
     their Production and Use of Said Ligands and Receptors" PCT/GB89/01344,
     filed November 13, 1989.
2    "Co-expression of Heteromeric Receptors" PCT/US90/02890, filed May 16,
     1990.
3    "Method for Isolating Receptors Having a Preselected Specificity"
     PCT/US90/02835, filed May 16, 1990.
4    "A new method for tapping the immunological repertoire" PCT/US90/02836,
     filed May 16, 1990.
5    "Cell-free Synthesis and Isolation of Novel Genes and Polypeptides"
     PCT/US90/06582, filed October 4, 1990.
6    "Methods for producing members of specific binding pairs" PCT/GB91/01134,
     filed July 10, 1991.
7    "Methods for producing members of specific binding pairs" PCT/GB92/00883,
     filed May 15, 1992.
8    "Treatment of Cell Populations" PCT/GB92/01483, filed August 10, 1992.
9    "Production of chimeric antibodies -- a combinational approach"
     PCT/GB92/01755, filed September 23, 1992.
10   "Production of anti-self antibodies from antibody segment repertoires and
     displayed on phage" PCT/GB92/02240, filed December 2, 1992.
11   "Methods for producing members of specific binding pairs" PCT/GB93/00605,
     filed March 24, 1993.
12   "SBP members with a chemical moiety covalently bound within the binding
     site; production and selection thereof" PCT/GB94/01422, filed June 30,
     1994.
13   "Retargetting antibodies" PCT/GB94/02019, filed September 16, 1994.
14   "Recombinant Binding Proteins and peptides" PCT/GB94/02662, filed December
     5, 1994.
15   "Labelling and selection of Specified Binding Molecules" PCT/GB97/01835,
     filed July 8, 1997.

                                       54
<PAGE>

                                 SCHEDULE 1.7

                               CAT PATENT RIGHTS

[***]

<PAGE>

                                 SCHEDULE 1.14

                             THIRD PARTY ROYALTIES

1.   License Agreement dated January 7, 1997 between CAT and MRC, with certain
     royalty rates, as may be amended from time to time, which shall include all
     royalty payments due to the Scripps Research Institute and Stratagene
     pursuant to an agreement dated 25 June 1999.

2.   Therapeutic Antibodies Agreement, dated December 31, 1997 between CAT and
     Dyax Corp., with a royalty rate of [***], as such agreement may be amended
     from time to time.

3.   Diagnostic Antibodies Agreement dated December 31, 1997 between CAT and
     Dyax Corp., with a royalty rate of [***], as such agreement may be amended
     from time to time.

4.   The Burnham License, as such agreement may be amended from time to time,
     with royalty rates of:

     .    $[***] on Net Sales of Licensed Products payable to Burnham;
     .    $[***] on Net Sales of Licensed Products payable to Integra; and
     .    $[***] payable to Burnham on sales of a product, whether an antibody-
          based or non-antibody-based antagonist, which would infringe a Valid
          Claim in the Dasch Patents, but not infringe a Valid Claim in the
          Licensed Patent Rights

     Capitalized terms used above are as defined in the Burnham License.

5.   Agreement dated December 18, 1997 between Genzyme and Insmed
     Pharmaceuticals, Inc. (as successor to Celtrix Pharmaceuticals, Inc.), with
     a royalty rate of [***], as such agreement has been and may be amended from
     time to time.